

Figure 1


Concentration (pg/mL)
3200
1600
800
400
200
100
50
n=20
n=155
n=18
n=72
n=155
n=16
n=72
n=165
n=16
IL-18 HV
IL-18 SLE
IL-18 LN
CXCL10 HV
CXCL10 SLE
CXCL10 LN
CCL2 HV
CCL2 SLE
CCL2 LN

Figure 2


Gene Expression (Log2)
12
11
10
9
Serum AMG811 Concentration (ng/mL)
0
10
100
1000
10000
6
5
4
3
2
1
0
-1
-2
Gene Expression
(SD from Healthy Controls)
Fold change (treated/pbo)
-1.5
1
1.5
Significance
0.001
0.01
0.05
0.1

Figure 3


Fold Change from Baseline
1.5
1
0.5
0
-0.5
-1
-1.5
-2
Dy15
Dy66
EOS
0mg
2mg
6mg
20mg
60mg
60mg/V
180mg

Figure 4


2 mg (n=3)
6 mg (n=3)
20 mg (n=3)
60 mg (n=3)
180 mg (n=3)
60 mg IV (n=3)
AMG 811 Serum Concentration (ng/mL)
100000
10000
1000
100
10
1
0
28
56
84
112
140
168
Time (day)

FIGURE 5


Serum Total IFNγ (pg/mL)
500
400
300
200
100
0
0
50
100
150
200
250
Time (day)
2 mg SC (n=3)
6 mg SC (n=3)
20 mg SC (n=3)
60 mg SC (n=3)
180 mg SC (n=3)
60 mg IV (n=3)


Serum Total IFNγ (pg/mL)
2000
1500
1000
500
0
0
50
100
150
200
250
Time (day)
2 mg SC (n=3)
6 mg SC (n=3)
20 mg SC (n=3)
60 mg SC (n=3)
180 mg SC (n=3)
60 mg IV (n=3)

FIGURE 6B


AMG 811 Signature ± 95% CI
500
400
300
250
200
150
00 mg
20 mg
60 mg
dose

Figure 7


D8
D15
D29
D57
D85
D113
EOS
Fold change from baseline
4
2
0
Dose
20 mg
5 mg
2.5 mg
Feature 8


D8
D15
D29
D57
D85
D113
EOS
60 mg
20 mg
Dose
Escalation
5 mg
Fold change from baseline
4
3
2


IP10 Fold Change from Baseline
4
2
1
-2
-4
N=32 sbj
D8
D15
D29
D57
D85
8
150
450
1500
4500
15000
Serum AMG 811 Concentration (ng/mL)

Figure 10


Gene Expression Level
Standard Deviations from Healthy Controls
Gene Expression (Log2)
D1
D15
Serum AMG 811 Concentration (ng/mL)
0
10
100
1000
10000
6
4
2
0
-2
13
12
11
10
9
8

Figure 11


24 HOUR URINE PROTEIN (grams/day)
0
1
2
3
4
5
6
7
8
9
B 15 29 57 85 113 141 168 EOS
B 15 29 57 85 113 141 168 EOS
STUDY DAY

Figure 12


SPOT URINE PROTEIN/CREATININE RATIO
0
2
4
6
8
10
12
14
16
B 15 29 57 71 85 113 141 168 EOS
STUDY DAY

Figure 13



Figure 14